StockUS listing USCVMAMEXHealthcareEarnings Deterioration

CEL-SCI Corp(CVM) Stock Analysis | Healthcare

USD --+0.00%
Reward30Low
Risk50Moderate
75%Data
Revenue down 63% YoY
USD —+0.00 (+0.00%) Previous close · AMEX
Market cap 21.28M
Reward Ratingⓘ30 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ50 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CVM to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is CEL-SCI Corp?

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.

AI Brief Pro

The brief on CEL-SCI Corp

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is CEL-SCI Corp?

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. The company is listed on the AMEX in USA, operating in the Healthcare sector, with a market capitalisation of 21.28M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (30)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.623
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
0
1100,000 shares
$138k
3-6months
0
0
6-9months
0
2400,000 shares
$479k
9-12months
0
246,412 shares
$250k